Previous 10 | Next 10 |
2023-12-19 09:08:37 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the topic of top penny stocks to buy may arouse controversy similar to apocryphal literature with spiritual implications. That might sound hyperbolic but generally, financial advisors...
2023-12-11 08:35:07 ET Affimed ( NASDAQ: AFMD ) shares erased premarket gains despite reporting encouraging data on its lead innate cell engager ( ICE ) acimtamig in patients with recurrent or refractory Hodgkin lymphoma patients who failed prior chemotherapy. Phase 1/2 ...
Data update from AFM24-102 Phase 1/2a combination study includes 15 heavily pre-treated patients from the EGFR-wildtype non-small cell lung cancer (NSCLC) expansion cohort Responses observed in 4 of 15 patients, including 1 confirmed partial response (PR), 1 unconfirmed complete response ...
In 32 patients with relapsed/refractory (r/r) Hodgkin lymphoma (HL) treated at the recommended phase 2 dose level (RP2D), the objective response rate (ORR) was 97% and the complete response (CR) rate was 78% In this cohort median EFS was 9.8 months with 84% patients alive at 12 months, and me...
Review clinical data of acimtamig in combination with cord-blood derived NK cells presented at ASH 2023; provide progress update on the LuminICE-203 Review clinical data for AFM24 in solid tumors Conference call/webcast on Monday, December 11, 2023 at 1:30 p.m. PST / 4:30 p.m. EST / 22:...
2023-11-30 15:42:00 ET More on Affimed Affimed N.V. (AFMD) Q3 2023 Earnings Call Transcript Affimed N.V. 2023 Q3 - Results - Earnings Call Presentation Affimed gains on FDA fast track tag for lymphoma therapy Seeking Alpha’s Quant Rating on Affimed ...
2023-11-14 13:57:07 ET Affimed N.V. (AFMD) Q3 2023 Results Earnings Conference Call November 14, 2023, 08:30 AM ET Company Participants Alexander Fudukidis - Director and Head of Investor Relations Adi Hoess - Chief Executive Officer Andreas Harstrick - Chief Med...
2023-11-14 06:33:03 ET More on Affimed Affimed gains on FDA fast track tag for lymphoma therapy Seeking Alpha’s Quant Rating on Affimed Historical earnings data for Affimed Financial information for Affimed For further details see: Affimed ...
Acimtamig (also known as AFM13) combination with AlloNK ® (also known as AB-101): Initiated LuminICE-203. Company on track to report initial data in H1 2024. Acimtamig: Received fast-track designation for the combination of acimtamig and AlloNK ® . LuminICE-203: Received...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
News, Short Squeeze, Breakout and More Instantly...
Affimed N.V. Company Name:
AFMD Stock Symbol:
NASDAQ Market:
The preliminary results from the phase 2 study investigating AFM24 in combination with the checkpoint inhibitor atezolizumab in patients with EGFR wild-type non-small cell lung cancer have been accepted for poster presentation MANNHEIM, Germany, April 24, 2024 (GLOBE NEWSWIRE) -- Affimed N....
Swire Pacific Ltd. ADR (Class A) (SWRAY) is expected to report for Q4 2023 Troika Media Group Inc. (TRKAQ) is expected to report for quarter end 2023-12-31 American Environmental Partners Inc. (AEPT) is expected to report for quarter end 2023-12-31 Veolia Environnement S.A. ADR (VEOEY...
AFM24 combination with atezolizumab (AFM24-102): Follow-up of the Phase 1/2a combination study confirmed four responses in the non-small cell cancer (NSCLC) EGFR -wildtype cohort: one complete response (CR), three partial responses (PR), and seven stable disease patients in the 15 heavily p...